The CD40 agonist HERA-CD40L results in enhanced activation of antigen presenting cells, promoting an anti-tumor effect alone and in combination with radiotherapy

Autor: Jamie Frankish, Debayan Mukherjee, Erminia Romano, Katharina Billian-Frey, Matthias Schröder, Karl Heinonen, Christian Merz, Mauricio Redondo Müller, Christian Gieffers, Oliver Hill, Meinolf Thiemann, Jamie Honeychurch, Tim Illidge, Jaromir Sykora

Publikováno v: Frontiers in Immunology, Vol 14 (2023)

IntroductionThe ability to modulate and enhance the anti-tumor immune responses is critical in developing novel therapies in cancer. The Tumor Necrosis Factor (TNF) Receptor Super Family (TNFRSF) are potentially excellent targets for modulation which

Externí odkaz: https://doaj.org/article/3a2c8f98856e4fc4a7c38804f359c93f

Akt inhibition improves long‐term tumour control following radiotherapy by altering the microenvironment

Autor: Emma J Searle, Brian A Telfer, Debayan Mukherjee, Duncan M Forster, Barry R Davies, Kaye J Williams, Ian J Stratford, Tim M Illidge

Publikováno v: EMBO Molecular Medicine, Vol 9, Iss 12, Pp 1646-1659 (2017)

Abstract Radiotherapy is an important anti‐cancer treatment, but tumour recurrence remains a significant clinical problem. In an effort to improve outcomes further, targeted anti‐cancer drugs are being tested in combination with radiotherapy. Her

Externí odkaz: https://doaj.org/article/94b34dde6bcb4bbb88dfef6a2ecc2928

IRF7 impacts on prostate cancer cell survival in response to radiation

Autor: Adam Pickard, Francesca Amoroso, Kelsey McCulloch, Andrew Erickson, Ashwin Sachdeva, Rebecca Steele, Debayan Mukherjee, Margaret Dellett, Jonathan McComb, Laura McCaffery, Claire A. Hart, Michael D. Brown, Simon McDade, David Waugh, Noel Clarke, Karl Butterworth, Tim Illidge, Tuomas Mirtti, Ian M. Overton, Ian G. Mills

Understanding the impact of radiotherapy on the evolution of treatment resistant prostate cancer is critical for selecting effective treatment combinations. Whilst activation of Type 1 interferon signalling is a hallmark of how cells respond to viral

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c32725fe5788159a4e2f72ed57adcae2
https://doi.org/10.1101/2022.09.23.509205

The effect of hypoxia on PD-L1 expression in bladder cancer

Autor: Sapna Lunj, Timothy M Illidge, Ananya Choudhury, Debayan Mukherjee, Peter Hoskin, Catharine M L West, Vicky Smith

Publikováno v: Smith, V, Mukherjee, D, Lunj, S, Choudhury, A, Hoskin, P, West, C & Illidge, T 2021, ' The effect of hypoxia on PD-L1 expression in bladder cancer ', BMC Cancer, vol. 21, no. 1, 1271, pp. 1271 . https://doi.org/10.1186/s12885-021-09009-7
BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)

Introduction Recent data has demonstrated that hypoxia drives an immunosuppressive tumour microenvironment (TME) via various mechanisms including hypoxia inducible factor (HIF)-dependent upregulation of programmed death ligand 1 (PD-L1). Both hypoxia

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7889a8b601ccc9677f3b6a50f193f125
https://research.manchester.ac.uk/en/publications/8e593886-dc69-4cf4-a3fb-4f3f419b9af4

Abstract 6236: Low CD8 T cells predicts benefit from hypoxia-modifying therapy in bladder cancer

Autor: Vicky Smith, Debayan Mukherjee, Anna Maria Tsakiroglou, Alexander Baker, Hitesh Mistry, Ananya Choudhury, Peter Hoskin, Tim Illidge, Catharine West

Publikováno v: Cancer Research. 82:6236-6236

Introduction: Hypoxia and an immunosuppressive tumor microenvironment (TME) are both independent negative prognostic factors that contribute to radiotherapy resistance in muscle-invasive bladder cancer (MIBC). Therefore, we sought to investigate the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::459815e7a9c47f1facd90702db8c0036
https://doi.org/10.1158/1538-7445.am2022-6236